MYO1B

Across TCGA pan-cancer cohorts, MYO1B Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MYO1B data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MYO1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, UCEC, and UCS are the cancer types where MYO1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.225	0.693	<.001	24	view →
UCEC	DFS	Median	All	0.976	0.617	.001	24	view →
UCS	OS	Median	II,III,IV	0.007	0.616	<.001	12	view →
SARC	DFS	Median	All	0.159	0.613	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	All	0.266	0.704	.004	6	view →
LUSC	OS	Median	III,IV	0.178	0.683	.040	6	view →
SKCM	OS	Median	III,IV	0.267	0.707	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MYO1B–LIHC (OS)

Open the LIHC breakdown →